Bender Robert & Associates Acquires New Shares in Evolus, Inc. (NASDAQ:EOLS)

Bender Robert & Associates bought a new stake in Evolus, Inc. (NASDAQ:EOLS) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 25,070 shares of the company’s stock, valued at approximately $277,000.

A number of other hedge funds have also made changes to their positions in the company. Charles Schwab Investment Management Inc. increased its holdings in Evolus by 173.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 418,576 shares of the company’s stock valued at $6,781,000 after acquiring an additional 265,635 shares in the last quarter. Ikarian Capital LLC purchased a new stake in Evolus in the 3rd quarter valued at approximately $4,184,000. Walleye Capital LLC purchased a new position in Evolus during the third quarter worth $3,438,000. Lord Abbett & CO. LLC raised its holdings in shares of Evolus by 23.4% in the third quarter. Lord Abbett & CO. LLC now owns 995,449 shares of the company’s stock worth $16,126,000 after acquiring an additional 188,685 shares during the last quarter. Finally, GSA Capital Partners LLP boosted its stake in shares of Evolus by 335.3% during the third quarter. GSA Capital Partners LLP now owns 120,964 shares of the company’s stock valued at $1,960,000 after acquiring an additional 93,176 shares during the last quarter. Hedge funds and other institutional investors own 90.69% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have issued reports on EOLS. Barclays raised their price target on shares of Evolus from $22.00 to $25.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 5th. HC Wainwright reiterated a “buy” rating and issued a $27.00 price target on shares of Evolus in a report on Wednesday, March 5th. Finally, Needham & Company LLC restated a “buy” rating and set a $22.00 price objective on shares of Evolus in a report on Wednesday, March 5th.

Evolus Stock Performance

NASDAQ:EOLS opened at $12.71 on Wednesday. The company has a market cap of $808.19 million, a P/E ratio of -13.97 and a beta of 1.28. The firm’s 50 day moving average is $12.98 and its two-hundred day moving average is $14.03. Evolus, Inc. has a fifty-two week low of $9.25 and a fifty-two week high of $17.82. The company has a quick ratio of 2.23, a current ratio of 2.47 and a debt-to-equity ratio of 20.58.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.